H.C. Wainwright Initiates Coverage on Acrivon Therapeutics (ACRV) With "Buy" Rating and $19 PT
On November 25, 2025, Acrivon Therapeutics, Inc. (NASDAQ:ACRV) saw H.C. Wainwright’s Emily Bodnar initiate coverage with a “Buy” rating and a $19 price target.



